Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen & Alzheimer's: Analgesic may protect against disease due to inhibition of amyloid-beta 42 peptide, a protein found in plaque that kills brain cells of Alzheimer's patients, researchers report in Nov. 8 Nature. Sascha Weggen, UC-San Diego, et al., found 250 mM ibuprofen dissolved in ethanol decreased Aß42 peptide in cultured cells by up to 80%. Also, ibuprofen treatment in three-month old mice "resulted in a highly significant 39% decrease in levels of Aß42...compared with mock-treated animals," researchers report. However, aspirin, naproxen, other NSAIDs showed negative results, indicating a lack of ability to lower Aß42 levels. Although researchers previously believed NSAIDs' mechanism of action was their anti-inflammatory properties, Weggen et al. note "this Aß42 activity may be an important criterion to consider in...trials of NSAIDs for the treatment of Alzheimer's disease"...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts